Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

@article{Meyer1996MetabolicIO,
  title={Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs},
  author={U. A. Meyer},
  journal={European Journal of Gastroenterology \& Hepatology},
  year={1996},
  volume={8},
  pages={S21-S25}
}
  • U. Meyer
  • Published 1 October 1996
  • Medicine
  • European Journal of Gastroenterology & Hepatology
Purpose: To analyse the metabolism of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole by cytochrome P450 (CYP) enzymes, and to assess the consequences for drug–drug interactions. Results of data analysis: Lansoprazole, omeprazole and pantoprazole are extensively metabolized by several human cytochromes P450, most prominently by mephenytoin hydroxylase (CYP2C19) and nifedipine hydroxylase (CYP3A4). Only pantoprazole is also metabolized to a significant extent by a… Expand
Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole
  • Ishizaki, Horai
  • Chemistry, Medicine
  • Alimentary pharmacology & therapeutics
  • 1999
TLDR
The metabolism of rabeprazole is less dependent on CYP2C19 and therefore is the least affected by this genetic polymorphism and the therapeutic effectiveness of proton pump inhibitors during the treatment of acid‐related diseases. Expand
Proton pump inhibitors--differences emerge in hepatic metabolism.
  • K. McColl, P. Kennerley
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2002
TLDR
Differences are emerging with respect to the mode of metabolism of proton pump inhibitors, and the possible benefits of the non-enzymatic metabolism of rabeprazole, require further investigation. Expand
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
TLDR
Concomitant intake of omeprazole, lansoprazole or pantoprazoles at high therapeutic doses does not affect the absorption and disposition of theophylline. Expand
Comparative Effects of Rabeprazole and Omeprazole on the Inducibility of Cytochrome P450-1A and Cytochrome P450-3A Isoenzymes in Human Hepatocytes, and Effects on Cyclosporin Metabolism in Human Liver Microsomes
TLDR
Rabeprazoles may have lower potential than omeprazole for causing CYP-mediated drug interactions, inasmuch as it does not induce CYP1A2 and only modestly induces CYP3A4 at high concentrations. Expand
Pharmacogenetics of the Proton Pump Inhibitors: A Systematic Review
TLDR
It is found that the relationship between CYP2C19 genetic polymorphism and clinical outcomes after PPI therapy has not yet been clearly delineated and may be a valuable clinical tool in select patients to ensure optimal PPI Therapy. Expand
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
TLDR
It is concluded that physicians prescribing moclobemide should pay attention to its pharmacokinetic interactions even on the first day of coadministration with CYP2C19 substrates. Expand
Proton pump inhibitors and their drug interactions: an evidence-based approach
The proton pump inhibitors (PPIs) are the most effective antisecretory agents used to treat acid-related disorders. As such, they are frequently prescribed for patients who are concurrently usingExpand
Proton pump inhibitors and their drug interactions: an evidence-based approach.
TLDR
The proton pump inhibitors are the most effective antisecretory agents used to treat acid-related disorders and are frequently prescribed for patients who are concurrently using other medications, but caution is indicated when certain drugs are co-prescribed with these agents. Expand
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors
TLDR
The potential for drug interactions should be taken into account when choosing a therapy for gastric acid-related disorders, especially for elderly patients in whom polypharmacy is common, or in those receiving a concomitant medication with a narrow therapeutic index. Expand
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
TLDR
Based on superior efficacy profiles, PPIs are the drugs of choice in managing patients with peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Expand
...
1
2
3
4
5
...